Breast Cancer Study: Towards Personalized Treatment
The largest-ever study to sequence the whole genomes of breast cancers has uncovered five new genes associated with the disease and 13 new mutational signatures that influence tumor development. Two studies from the Wellcome Genome Campus pinpoint where genetic variations in breast cancers occur. [Press release from European Bioinformatics Institute EMBL-EBI discussing online prepublication in Nature and Nature Communications] Press Release|Abstract (Nature)|Full Article (Nature Communications)
GR and ER Co-Activation Alters the Expression of Differentiation Genes and Associates with Improved ER+ Breast Cancer Outcome
To understand the mechanism by which glucocorticoid receptor (GR) expression is associated with a better ER+ breast cancer (BC) outcome, the global effect of GR-mediated transcriptional activation in ER+ BC cells was studied. Analysis of GR chromatin immunoprecipitation followed by high-throughput sequencing in ER+/GR+ MCF-7 cells revealed that upon co-activation of GR and ER, GR chromatin association became enriched at proximal promoter regions. [Mol Cancer Res] Abstract
The Intestinal Microbiome and Estrogen Receptor-Positive Female Breast Cancer
The reviewers discuss how the intestinal bacterial microbiome and in particular how an ‘estrobolome,’ the aggregate of enteric bacterial genes capable of metabolizing estrogens, might affect women’s risk of developing postmenopausal estrogen receptor-positive breast cancer. Estrobolome composition is impacted by factors that modulate its functional activity. [J Natl Cancer Inst] Full Article
Visit our reviews page to see a complete list of reviews in the mammary cell research field.
INDUSTRY NEWS
Alvogen Launches First Generic Equivalent of Zoladex
Alvogen announced the launch of the first generic equivalent of Zoladex™ in Central and Eastern Europe. The product will be marketed in two strengths (3.6mg and 10.8mg) under the brand name Reseligo™ and will be launched in Bulgaria, Croatia, Baltics, Romania, Hungary, Iceland and Poland. [Alvogen] Press Release